|
Carcinoma, Ovarian Epithelial
|
|
0.030 |
GeneticVariation
|
BEFREE |
The ITGB3 Leu33Pro polymorphism does not modify breast or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers.
|
19876733 |
2010 |
|
ovarian neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
The ITGB3 Leu33Pro polymorphism does not modify breast or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers.
|
19876733 |
2010 |
|
Malignant neoplasm of ovary
|
|
0.030 |
GeneticVariation
|
BEFREE |
The ITGB3 Leu33Pro polymorphism does not modify breast or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers.
|
19876733 |
2010 |
|
Malignant neoplasm of ovary
|
|
0.030 |
GeneticVariation
|
BEFREE |
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
|
17220212 |
2007 |
|
ovarian neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
|
17220212 |
2007 |
|
Carcinoma, Ovarian Epithelial
|
|
0.030 |
GeneticVariation
|
BEFREE |
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
|
17220212 |
2007 |
|
ovarian neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
Integrin beta(3) Leu33Pro homozygotes have an increased risk of ovarian cancer.
|
16322334 |
2005 |
|
Malignant neoplasm of ovary
|
|
0.030 |
GeneticVariation
|
BEFREE |
Integrin beta(3) Leu33Pro homozygotes have an increased risk of ovarian cancer.
|
16322334 |
2005 |
|
Carcinoma, Ovarian Epithelial
|
|
0.030 |
GeneticVariation
|
BEFREE |
Integrin beta(3) Leu33Pro homozygotes have an increased risk of ovarian cancer.
|
16322334 |
2005 |
|
Myocardial Infarction
|
|
0.020 |
GeneticVariation
|
BEFREE |
We examined the potential role of polymorphisms of the platelet genes GP1BA (rs2243093, rs6065 and VNTR), ITGB3 (rs5918), ITGA2 (rs938043469) and P2RY12 (rs2046934, rs6801273 and rs6798347) as risk factors for myocardial infarction (MI).
|
30143348 |
2018 |
|
Coronary Artery Disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
The univariate analysis indicated that the five variants; rs1800595 (FVR2; factor 5), rs1801133 (MTHFR; 5,10-methylenetetrahydrofolate reductase), rs5918 (HPA-1; human platelet antigen 1), rs1799752 (ACE; angiotensin-converting enzyme), and rs7412 and rs429358 (ApoE; apolipoprotein E) were significantly associated with CAD susceptibility under different genetic models.
|
28086795 |
2017 |
|
Cardiovascular Diseases
|
|
0.020 |
GeneticVariation
|
BEFREE |
A total of nine gene variants/polymorphisms - F5 (Leiden - R5 06Q, rs6025), F2 (20210G > A, rs1799963), F13A1 (V34L, rs5985), MTHFR (677C > T - A222V, rs1801133), MTHFR (1298A > C - E429A, rs1801131), FGB (-455G > A -c.-463G > A; rs1800790), SERPINE1 (PAI14G/5G - rs1799889), ACE (ACE I/D, rs1799752), ITGB3 (GPIIIa L33P, rs5918) and the APOE E2/E3/E4 alleles (rs7412, rs429358) - were genotyped in 200 newly diagnosed ischemic stroke (IS) patients, 165 patients with ischemic coronary heart disease (CHD) and 159 controls with no cerebroor cardiovascular disease (non-CVD).
|
27629735 |
2016 |
|
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
Herein, we evaluated the predictive potential of three germline single nucleotide polymorphisms (SNPs) in the integrin β3 gene (rs3809865, rs5918 and rs4642) to predict the risk of venous thromboembolism (VTE) in colorectal cancer (CRC) patients, which is one of the leading causes of death among cancer patients.
|
26440977 |
2015 |
|
Coronary Artery Disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
Platelet glycoprotein IIIa Leu33Pro gene polymorphism and coronary artery disease: A meta-analysis of cohort studies.
|
25167197 |
2015 |
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Herein, we evaluated the predictive potential of three germline single nucleotide polymorphisms (SNPs) in the integrin β3 gene (rs3809865, rs5918 and rs4642) to predict the risk of venous thromboembolism (VTE) in colorectal cancer (CRC) patients, which is one of the leading causes of death among cancer patients.
|
26440977 |
2015 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Herein, we evaluated the predictive potential of three germline single nucleotide polymorphisms (SNPs) in the integrin β3 gene (rs3809865, rs5918 and rs4642) to predict the risk of venous thromboembolism (VTE) in colorectal cancer (CRC) patients, which is one of the leading causes of death among cancer patients.
|
26440977 |
2015 |
|
Coronary Thrombosis
|
|
0.020 |
GeneticVariation
|
BEFREE |
A common isoform of integrin β3, Leu33Pro is associated with enhanced platelet function and increased risk for coronary thrombosis and stroke, although these findings remain controversial.
|
24695082 |
2014 |
|
Cerebrovascular accident
|
|
0.020 |
GeneticVariation
|
BEFREE |
A common isoform of integrin β3, Leu33Pro is associated with enhanced platelet function and increased risk for coronary thrombosis and stroke, although these findings remain controversial.
|
24695082 |
2014 |
|
Cerebrovascular accident
|
|
0.020 |
GeneticVariation
|
BEFREE |
This is the first study to demonstrate associations between stroke functional outcome and 2 COX-2 variants (rs20417 and rs5275) and a GPIIIa variant (rs5918).
|
20472470 |
2011 |
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The ITGA2 1648G> and the ITGB3 176T>C polymorphism were not associated with colorectal cancer.
|
18836731 |
2009 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
The ITGB3 176T>C polymorphisms was not associated with breast cancer susceptibility.
|
16317580 |
2006 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The ITGB3 176T>C polymorphisms was not associated with breast cancer susceptibility.
|
16317580 |
2006 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
We previously demonstrated that integrin beta(3) Leu33Pro homozygotes have an increased risk of cancer, possibly most pronounced for ovarian cancer.
|
16322334 |
2005 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Leu33Pro heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers had odds ratios for breast cancer of 1.0 (95% confidence interval: 0.8-1.1), 0.8 (0.5-1.2) and 1.0 (0.8-1.1), respectively.
|
15970922 |
2005 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
Leu33Pro heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers had odds ratios for breast cancer of 1.0 (95% confidence interval: 0.8-1.1), 0.8 (0.5-1.2) and 1.0 (0.8-1.1), respectively.
|
15970922 |
2005 |